SUBSCRIBE
SUBSCRIBE

Mesoblast Limited Emerging Portfolio of Clinical Products Underpin Commercial Strategic Objectives

February 26, 2009 | 
1 min read

Melbourne, Feb 26, 2009 (ABN Newswire) - Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced its half-yearly results.

Asia Australia
MORE ON THIS TOPIC
Pictured: AstraZeneca building in Gothenburg/iStoc
China
AstraZeneca Names New International Operations Lead Amid Probe on China Exec
December 5, 2024
 · 
3 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Chinese flag with digital matrix -Innovation Concept - Digital Tech Wallpaper - 3D illustration
Weight loss
Novo’s Wegovy Launched in China at a Fraction of US Price
November 18, 2024
 · 
1 min read
 · 
Annalee Armstrong
Brain shaped white jigsaw puzzle on blue background. Mental health and problems with memory.
Alzheimer’s disease
Eisai Cuts Fiscal 2024 Guidance for Biogen-Partnered Leqembi as Sales Disappoint Analysts
November 8, 2024
 · 
2 min read
 · 
Tristan Manalac